Anika Therapeutics (NASDAQ:ANIK) Share Price Breaks Below 200 Day Moving Average After Earnings Miss

Anika Therapeutics Inc. (NASDAQ:ANIK) crossed below its two hundred day moving average during trading on Friday following a weaker than expected earnings announcement. The stock has a two hundred day moving average of $16.25 and traded as low as $13.90. Anika Therapeutics shares last traded at $14.55, with a volume of 294,030 shares.

The biotechnology company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.13). The company had revenue of $30.59 million for the quarter, compared to analyst estimates of $29.44 million. Anika Therapeutics had a positive return on equity of 0.20% and a negative net margin of 3.14%.

Key Anika Therapeutics News

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 10% year over year to $30.59 million, beating the cited analyst estimate of $29.44 million. Commercial-channel revenue grew 17%, with Integrity revenue up more than 30%. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Anika raised the lower end of its 2026 revenue guidance and increased its adjusted EBITDA outlook. It forecast revenue of $119.6 million to $124.1 million, a range that includes the $121.6 million consensus estimate. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company secured a new 10-year Hyvisc partnership with improved economics and reintroduced a Hyaff product for non-orthopedic original-equipment-manufacturer customers, offering potential longer-term commercial support. Anika Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted EPS was reported at $0.29, above Zacks’ $0.17 estimate, while the cited results also show a GAAP loss of $0.02 per share. Analyst estimates differ across reports, making the earnings comparison mixed. Anika Therapeutics Beats Q3 Earnings and Revenue Estimates
• Negative Sentiment: The GAAP loss and reported EPS misses against some analyst benchmarks may have weighed on sentiment, despite the revenue beat and stronger adjusted-EPS comparison. Anika Therapeutics GAAP EPS and Revenue Results

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ANIK shares. Barrington Research set a $21.00 target price on shares of Anika Therapeutics in a research note on Thursday, July 30th. Wall Street Zen upgraded shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. B. Riley Financial started coverage on Anika Therapeutics in a research note on Friday, September 18th. They issued a “buy” rating and a $23.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Monday, September 21st. Finally, Zacks Research downgraded Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $22.00.

Institutional Investors Weigh In On Anika Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Man Group plc acquired a new stake in shares of Anika Therapeutics in the 2nd quarter valued at about $2,059,000. Globeflex Capital L P purchased a new position in Anika Therapeutics during the 2nd quarter worth $1,282,000. Hsbc Holdings PLC acquired a new stake in Anika Therapeutics in the second quarter valued at about $727,000. BlackRock Inc. acquired a new stake in shares of Anika Therapeutics in the 2nd quarter valued at approximately $21,209,000. Finally, Deutsche Bank AG purchased a new stake in shares of Anika Therapeutics during the 2nd quarter worth $5,172,000. 91.53% of the stock is owned by hedge funds and other institutional investors.

Anika Therapeutics Stock Down 24.7%

The stock has a market cap of $194.68 million, a PE ratio of -53.89, a P/E/G ratio of 13.86 and a beta of 0.21. The business’s fifty day moving average is $20.38 and its 200 day moving average is $16.25.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.